Company intelligence / Profile preview

Athyrium Capital Management

New York City, New York, United States

Ownership: Private
Employees: ~28
Development stage: Other

Overview

Athyrium Capital Management is a specialized asset management firm founded in 2008, dedicated to structured investments in the global healthcare and life sciences sectors, including biotech, pharma, medical devices, healthcare services, and health tech. It acts as an investor rather than a therapeutic developer, so does not have its own clinical results or development pipeline[1][3][5].

Industry: Investors

Partnerships

Neuberger Berman (strategic partnership as co-fund manager and sub-advisor)[1][7]Numerous portfolio companies in biotech, pharma, medical devices, healthcare services, and healthcare technology, including recent relationships with Basilea Pharmaceutica, Calliditas Therapeutics, Coherus Biosciences, Esperion Therapeutics[3]

Beyond the preview

Go deeper on Athyrium Capital Management.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Athyrium Capital Management.

Explore the full profile